An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases
Clinical trial NCT07461727 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07461727
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-10
- Primary completion
- 2027-01-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.